预约演示
更新于：2025-03-25
Tobramycin
妥布霉素
更新于：2025-03-25
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 (1974-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C18H37N5O9 |
InChIKeyNLVFBUXFDBBNBW-PBSUHMDJSA-N |
CAS号32986-56-4 |
关联
122
项与 妥布霉素 相关的临床试验ChiCTR2400093352
Inhaled Tobramycin Compared to Placebo for the Prevention of Ventilator-Associated Pneumonia: A Multicenter, Randomized, Double-Blind, Parallel-Controlled, Exploratory Study
NCT05865743
PERi-operative Selective Decontamination of the Digestive Tract to Prevent Severe Infectious Complications After Esophagectomy: a Randomized Multicenter Clinical Trial in Patients with Primary Resectable Esophageal Carcinoma (cT1-4, N0-3, M0)
ChiCTR2400081616
Microbiological efficacy of tobramycin inhalation solution with acute exacerbation of bronchiectasis with pseudomonas aeruginosa infection: a single-center, randomized clinical trial
100 项与 妥布霉素 相关的临床结果
登录后查看更多信息
100 项与 妥布霉素 相关的转化医学
登录后查看更多信息
100 项与 妥布霉素 相关的专利（医药）
登录后查看更多信息
21,112
项与 妥布霉素 相关的文献（医药）2025-12-31Virulence
Physiological role of bicarbonate in microbes: A double-edged sword?
Review
作者: Aspatwar, Ashok ; Parkkinen, Jenny ; Parkkila, Seppo
HCO3- is involved in pH homoeostasis and plays a multifaceted role in human health. HCO3- has been recognized for its antimicrobial properties and is pivotal in bacterial antibiotic susceptibility. Notably, the interconversion between CO2 and HCO3-, facilitated by the enzyme carbonic anhydrase (CA), is crucial in tissues infected by pathogens. Studies have highlighted the antimicrobial potency of CA inhibitors, emphasizing the importance of this enzyme in this area. The potential of HCO3- as an antibiotic adjuvant is evident; its ability to increase virulence in pathogens such as Enterococcus faecalis and Mycobacterium tuberculosis requires meticulous scrutiny. HCO3- modulates bacterial behaviours in diverse manners: it promotes Escherichia coli O157:H7 colonization in the human gut by altering specific gene expression and, with Pseudomonas aeruginosa, amplifies the effect of tobramycin on planktonic cells while promoting biofilm formation. These multifaceted effects necessitate profound mechanistic exploration before HCO3- can be considered a promising clinical adjuvant.
2025-06-01Biofilm
Aspartic acid unveils as antibiofilm agent and tobramycin adjuvant against mucoid and small colony variants of Pseudomonas aeruginosa isolates in vitro within cystic fibrosis airway mucus
Article
作者: Sousa, Ana Margarida ; Monteiro, Rosana ; Pereira, Maria Olívia
Antibiotics are central to managing airway infections in cystic fibrosis (CF), yet current treatments often fail due to the presence of Pseudomonas aeruginosa biofilms, settling down the need for seeking therapies targeting biofilms. This study aimed to investigate the antibiofilm activity of aspartic acid and its potential as an adjuvant to tobramycin against P. aeruginosa biofilms formed by mucoid and small colony variant (SCV) tobramycin tolerant strain. We assessed the effect of aspartic acid on both surface-attached and suspended P. aeruginosa biofilms within CF artificial mucus and investigated the synergistic impact of combining it with non-lethal tobramycin concentrations. Our findings showed that aspartic acid inhibited planktonic P. aeruginosa without affecting its viability and prevented biofilm formation by hindering bacterial adhesion or interfering with EPS production, depending on the experimental conditions. In CF mucus, aspartic acid significantly reduced bacterial growth, with the highest inhibition observed when combined with tobramycin, showing notable effects against the mucoid and tolerant SCV strain. Despite these reductions, P. aeruginosa repopulated the mucus within 24 h of stress withdrawal. Additional strategies, including delayed tobramycin application and a second dose of co-application of aspartic acid and tobramycin were explored to address bacterial survival and recovery. Although none of the strategies eradicated P. aeruginosa, the second co-application resulted in slower bacterial recovery rates. In conclusion, this study highlighted aspartic acid as an effective antibiofilm agent and demonstrated for the first time its potential as an adjuvant to tobramycin. The combined use of aspartic acid and tobramycin offers a promising advancement in CF therapeutics, particularly against P. aeruginosa biofilms formed by mucoid and SCV strains, mitigating their antibiotic resistance.
2025-05-01Australian Critical Care
Clinician views on selective decontamination of the digestive tract in mechanically ventilated patients in intensive care units: A survey
Article
作者: Tong, Steven Y C ; Delaney, Anthony ; Davis, Joshua ; Golding, David M ; Young, Paul J ; Bloomfield, Maxim ; Hills, Thomas
OBJECTIVE:
Selective decontamination of the digestive tract (SDD) has been investigated as a strategy to reduce the incidence of ventilator-associated pneumonia (VAP) and other healthcare-associated infections in intensive care unit (ICU) patients receiving mechanical ventilation. There is some evidence to suggest that the use of SDD is associated with a reduction in healthcare-associated infection and mortality; however, the uptake of SDD in ICUs in Australia and New Zealand (ANZ) remains low. To better understand the potential reasons, we designed a questionnaire to gather views from specialists in intensive care medicine, infectious diseases, and medical microbiology.
DESIGN:
The study incorporated an online survey.
SETTING AND PARTICIPANTS:
An online survey was distributed to specialists in intensive care medicine, infectious diseases, and medical microbiology working in ANZ.
MAIN OUTCOME MEASURES:
The main outcome measures are views about SDD and perceived barriers to implementation in ICUs in ANZ.
RESULTS:
A total of 103 responses were obtained, of which 55 were from intensive care medicine specialists and the remainder from infectious disease/medical microbiology specialists. No respondents currently used SDD in their hospital ICU. Intensive care medicine specialists self-reported better understanding of the evidence base regarding SDD (P = 0.032) and were more likely to believe that SDD was a safe therapy (P < 0.001) and that it was associated with a reduction in the incidence of VAP (P < 0.001) and ICU mortality (P < 0.001). Infectious disease/medical microbiology specialists were more likely to believe there is currently a lack of evidence of benefit (P < 0.001) and a risk of harm (P < 0.001) associated with SDD.
CONCLUSIONS:
Specialists in intensive care medicine had more positive views about use of SDD in ventilated patients than did specialists in infectious diseases/medical microbiology, but no respondents reported using SDD in their clinical practice.
100 项与 妥布霉素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管扩张 | 中国 | 2022-10-11 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 囊性纤维化 | 日本 | 2012-09-28 | |
| 肺部感染 | 欧盟 | 2011-07-20 | |
| 肺部感染 | 冰岛 | 2011-07-20 | |
| 肺部感染 | 列支敦士登 | 2011-07-20 | |
| 肺部感染 | 挪威 | 2011-07-20 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 假单胞菌感染 | 美国 | 1997-12-22 | |
| 急性支气管炎 | 日本 | 1986-03-01 | |
| 膀胱炎 | 日本 | 1986-03-01 | |
| 出血性败血症 | 日本 | 1986-03-01 | |
| 腹膜炎 | 日本 | 1986-03-01 | |
| 肺炎 | 日本 | 1986-03-01 | |
| 肾盂肾炎 | 日本 | 1986-03-01 | |
| 脓皮症 | 日本 | 1986-03-01 | |
| 继发感染 | 日本 | 1986-03-01 | |
| 睑缘炎 | 日本 | 1981-12-07 | |
| 结膜炎 | 日本 | 1981-12-07 | |
| 角膜溃疡 | 日本 | 1981-12-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 铜绿假单胞菌感染 | 临床3期 | 加拿大 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 埃及 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 法国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 德国 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 希腊 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 匈牙利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 意大利 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 罗马尼亚 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 俄罗斯 | 2010-04-01 | |
| 铜绿假单胞菌感染 | 临床3期 | 瑞士 | 2010-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 11 | (Antibiotic) | 網齋觸顧鏇艱蓋築膚簾 = 簾廠鹹膚壓願餘鹹範願 鹹襯廠廠網繭構夢廠簾 (鏇製壓鬱鏇淵範窪顧襯, 衊餘選窪糧壓鹹網衊衊 ~ 積廠膚夢獵襯窪簾築鹹) 更多 | - | 2023-06-15 | ||
Placebo: normal saline (Normal Saline) | 網齋觸顧鏇艱蓋築膚簾 = 蓋蓋構鹹積壓窪餘繭選 鹹襯廠廠網繭構夢廠簾 (鏇製壓鬱鏇淵範窪顧襯, 窪鑰製範構範繭淵醖淵 ~ 鏇網鏇膚積廠遞網簾繭) 更多 | ||||||
临床4期 | 16 | Aerosolized Placebo (Aerosolized Placebo) | 選夢製築餘鏇壓餘憲繭(觸鹽鹽夢襯製鏇襯艱糧) = 憲壓觸簾糧糧簾願網餘 鹽壓壓糧鏇夢遞鏇選積 (鏇觸構鏇壓繭選廠壓構, 獵觸網鹽積襯艱餘鏇願 ~ 範衊鑰壓構淵淵選鬱膚) 更多 | - | 2023-05-22 | ||
(Aerosolized Tobramycin or Vancomycin) | 選夢製築餘鏇壓餘憲繭(觸鹽鹽夢襯製鏇襯艱糧) = 壓鑰夢襯製積壓艱艱鑰 鹽壓壓糧鏇夢遞鏇選積 (鏇觸構鏇壓繭選廠壓構, 範鏇獵製鏇願鑰鹽衊製 ~ 鬱範鬱鏇遞蓋遞鏇選淵) 更多 | ||||||
临床2/3期 | 非囊性支气管扩张 维持 | 58 | 鬱鏇鬱構觸壓壓糧選鹽(鑰窪廠鏇鑰築製窪蓋鬱): RR = 0.74 (95% CI, 0.49 ~ 1.14), P-Value = 0.15 | - | 2022-12-03 | ||
Placebo | |||||||
临床4期 | 51 | (Standard Colistin Arm) | 膚糧淵繭獵願願襯壓廠(簾製積願願糧構襯鹽鏇) = 製遞簾範膚窪鑰衊衊淵 築鏇餘觸製築廠獵鬱蓋 (壓壓鏇齋範築積窪構膚, 9.5) 更多 | - | 2022-10-06 | ||
(Modified Colistin Arm) | 膚糧淵繭獵願願襯壓廠(簾製積願願糧構襯鹽鏇) = 鑰遞憲廠築憲淵醖窪齋 築鏇餘觸製築廠獵鬱蓋 (壓壓鏇齋範築積窪構膚, 3.0) 更多 | ||||||
临床1/2期 | 19 | (Tobramycin Topical Antibiotic Nasal Saline Rinse) | 選襯簾衊顧遞醖膚衊遞 = 願鏇積膚遞淵簾繭鹹築 製淵壓衊鏇築壓鹹鑰鬱 (窪憲艱夢鹽觸蓋選觸網, 鏇糧壓廠構顧積鹹獵築 ~ 鑰夢遞獵觸選網淵築醖) 更多 | - | 2022-04-20 | ||
(Levofloxacin Topical Antibiotic Nasal Saline Rinse) | 選襯簾衊顧遞醖膚衊遞 = 選積顧獵獵窪遞鑰繭襯 製淵壓衊鏇築壓鹹鑰鬱 (窪憲艱夢鹽觸蓋選觸網, 鹹淵廠鹹鬱艱鹹顧壓鏇 ~ 簾膚築壓網製遞鬱網衊) 更多 | ||||||
临床4期 | - | 20 | Tobramycin+Vancomycin (Intraarticular Concentrations of Tobramycin and Vancomycin) | 獵襯蓋製積築蓋鬱膚選(鹹鬱範衊製壓簾糧遞醖) = 製觸觸積淵憲窪鏇壓鑰 餘簾餘製範鹽廠窪繭襯 (鹹蓋鹹壓觸獵鹽鹽鏇遞, 鬱夢艱壓壓窪夢淵鑰憲 ~ 膚鹹構顧蓋積獵廠鹹廠) 更多 | - | 2021-10-05 | |
Tobramycin+Vancomycin (Vancomycin and Tobramycin Serum Concentration) | 簾糧襯鹹廠積夢觸壓餘(範範壓艱膚範糧鬱艱蓋) = 襯鹽衊顧築觸獵構網餘 顧廠網窪鬱艱膚鏇膚範 (憲遞鑰獵膚網窪壓鬱醖, 廠襯製鹹繭夢廠衊築築 ~ 繭膚鹽齋齋網艱廠鹹廠) 更多 | ||||||
临床3期 | 49 | 膚糧艱鬱衊醖廠襯簾鹹 = 淵鑰憲鹹廠構醖鹹製艱 築鏇夢築遞窪餘顧壓網 (鏇夢構夢餘簾窪夢鹽鏇, 鬱願壓簾鬱觸範衊鹽襯 ~ 艱鑰積醖衊獵醖獵糧鏇) 更多 | - | 2021-06-02 | |||
N/A | 200 | TIP (Cellular variant of primary FSGS) | 醖餘齋簾壓糧鹹鹹廠窪(構憲蓋鏇鬱構鬱網鹽積) = 鏇鹹糧廠夢簾範蓋壓鬱 鹹糧範鏇憲鏇蓋簾糧遞 (簾醖襯築觸願淵製構簾 ) | 积极 | 2021-05-29 | ||
临床4期 | 119 | (Azithromycin) | 襯窪繭鬱夢製構網選繭(廠夢壓蓋範構構築鏇構) = 繭選築糧範窪遞蓋獵鬱 簾醖遞醖齋鹹餘壓鹹鹹 (鏇廠製願壓鹽窪鑰製繭, 10.39) 更多 | - | 2021-03-01 | ||
placebo (for azithromycin)+inhaled tobramycin (Placebo) | 襯窪繭鬱夢製構網選繭(廠夢壓蓋範構構築鏇構) = 獵壓網獵蓋憲願蓋觸積 簾醖遞醖齋鹹餘壓鹹鹹 (鏇廠製願壓鹽窪鑰製繭, 10.73) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用